1:2 Bonus Shares: 9th August - Record Date, Q1 PAT Falls 25%; Check Stock Name

Gujarat Themis Biosyn Limited was established in 1981 as a joint venture between GIIC Ltd. and Chemosyn (P) Ltd. It began manufacturing in August 1985. Since 2007, it has been actively administered by Themis Medicare Ltd. (a joint venture with Gedeon Richter Ltd. in Hungary). In June 1991, it was acquired by the Yuhan Group of South Korea and the Pharmaceutical Business Group (India) Ltd. (PBG), a unique partnership of five rival pharma companies: Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus), and Lyka Labs Ltd.

Gujarat Themis Biosyn Record Date For Bonus Shares

"The Company has fixed Friday, 9th August, 2024 as the "Record Date" for the purpose of determining the eligibility of shareholders for issuance of Bonus Shares pursuant to Regulation 42 of The SEBI LODR, Regulations, 2015. The resolution for issuance of Equity Bonus shares has been already approved by the shareholders at the 43rd AGM held on 23rd July, 2024," said Gujarat Themis Biosyn in a stock exchange filing on 26th July.

The Board of Directors on 14th May, 2024 had considered and approved the issue of 1 (One) bonus share for every 2 (Two) equity shares held by the equity shareholders of the company as on 'Record Date'.

Gujarat Themis Biosyn Q1FY25 Results

In the first quarter of FY25, Gujarat Themis Biosyn revealed a 25.3% decrease in net profit at Rs 13.24 crore, down from Rs 17.72 crore during the same time the previous year. In the quarter that ended on June 30, 2024, the firm recorded a 21.7% YoY decline in net sales to Rs 38.83 crore. In the June-24 quarter, total operating expenses dropped by 22.2% to Rs 20.28 crore. In Q1 FY25, the company's profit before tax dropped by 25% to Rs 17.86 crore from Rs 23.81 crore in the same quarter the previous year.

Dr. Sachin Patel, Director said, "We have entered the new fiscal year on a positive note, with performance in line with expectations during the first quarter. Sale of built-up inventory in the previous quarters translated into relatively lower sales this quarter. However, production capacity continued to be at optimum levels and demand for both our products remains very strong. With respect to our ongoing capex, about half of our new R&D facility is operational wherein new molecule development is underway. More R&D sections are expected to be commissioned in the next few months. In regards to our API block, the plant and lab work is ready and qualification of equipment is going on. We expect to begin batches in the pilot plant in the next couple of months".

"We are also happy to share that civil construction of our additional fermentation capacity is almost halfway completed. Overall, the capex execution is progressing as per plans. In Q1 FY25, we reported a top line of Rs. 38.83 crores, while EBITDA and PAT stood at Rs. 18.55 crores and Rs. 13.24 crores, respectively. Operational efficiency measures and lower raw material costs, offset the impact of investments towards strengthening our talent pool, thereby improving EBITDA margin. The EPS (for each share of face value Re. 1) for the quarter is Rs. 1.82, while TTM EPS stands at Rs. 8.14," he further added.